DelveInsight’s ‘Lung Adenocarcinoma Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Lung Adenocarcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Lung Adenocarcinoma pipeline domain.
For Lung Adenocarcinoma emerging drugs, the Lung Adenocarcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
To know more about Lung Adenocarcinoma Pipeline Report offerings, click here @ Lung Adenocarcinoma Pipeline Insight
Key Takeaways from the Lung Adenocarcinoma Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Lung Adenocarcinoma pipeline landscape @ Lung Adenocarcinoma Pipeline Outlook
Lung Adenocarcinoma Overview
Lung adenocarcinoma is the most common kind of primary lung cancer in the United States. It is classed as non-small cell lung cancer (NSCLC) and is closely associated to prior smoking. While the incidence and mortality rates have reduced, it remains the leading cause of cancer death in the United States. Adenocarcinoma of the lung arises mostly from the mucosal glands and accounts for around 40% of all lung cancers. It is the most common type in those who have never smoked. Lung adenocarcinoma is most typically found in the lung’s periphery, but it can also be found in scars or areas of chronic inflammation. Tobacco smoking is by far the most important risk factor for any type of lung cancer, including adenocarcinoma. Because tobacco smoke contains several carcinogens, primary or secondary exposure increases risk proportionally to exposure level. various risk factors for lung adenocarcinoma include a family history of the disease and occupational exposure to various agents such as silica, asbestos, radon, heavy metals, and diesel fumes. The most common cause of carcinogenesis in NSCLC is genetic mutations in the p53 gene, which occur in 52% of cases.
Find out more about Lung Adenocarcinoma medication @ New Drug for Lung Adenocarcinoma
Lung Adenocarcinoma Treatment Analysis: Drug Profile
Bemcentinib: BerGenBio
Bemcentinib is a first-in-class, selective, once-daily oral AXL receptor tyrosine kinase (AXL) inhibitor that is a viable therapeutic target for critical disorders. Recent research in cancer has revealed that AXL signaling plays an important role in tumor proliferation, survival, metastasis, and resistance to therapy. AXL is also known to play a crucial role in virus transport into cells, and once within the cell, AXL signaling enhances virus engulfment, enhancing infectivity. It is now in the Phase II stage of clinical trial evaluation to treat patients with Adenocarcinoma of the Lung.
Letaplimab (IBI188): Innovent Biologics
Innovent Biologics’ IBI188 (letaplimab) is a recombinant completely humanized IgG4 monoclonal antibody that targets CD47. CD47 is a transmembrane protein that inhibits macrophage phagocytosis by attaching to the signaling regulatory protein (SIRP) on the macrophage’s surface and sending a “don’t eat me” signal. IBI188 (letaplimab) increased phagocytosis of tumor cells and cross-activated T lymphocytes after inhibiting this myeloid checkpoint. IBI188 (letaplimab) has a distinct target, a clear mechanism of action, and considerable efficacy in preclinical studies. The escalation of all preset doses was accomplished in phase 1a clinical data, with the highest exploratory dose of 30mg/kg QW. There was no dose-limiting toxicity in any of the dosage groups, and IBI188 (letaplimab) was generally well tolerated.
Key Lung Adenocarcinoma Therapies and Companies
Learn more about the novel and emerging Lung Adenocarcinoma pipeline therapies @ Lung Adenocarcinoma Clinical Trials
Lung Adenocarcinoma Therapeutics Assessment
By Product Type
By Stage
By Route of Administration
By Molecule Type
Scope of the Lung Adenocarcinoma Pipeline Report
Dive deep into rich insights for drugs used for Lung Adenocarcinoma treatment; visit @ Lung Adenocarcinoma Drugs
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Lung Adenocarcinoma Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
Lung Adenocarcinoma Pipeline Therapeutics
6.
Lung Adenocarcinoma Pipeline: Late-Stage Products (Phase III)
7.
8.
Lung Adenocarcinoma Pipeline: Mid-Stage Products (Phase II)
9.
Lung Adenocarcinoma Pipeline: Early Stage Products (Phase I)
10.
Lung Adenocarcinoma Therapeutic Assessment
11.
Inactive Lung Adenocarcinoma Products
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Key Lung Adenocarcinoma Companies
14.
Key Lung Adenocarcinoma Products
15.
Lung Adenocarcinoma Unmet Needs
16.
Lung Adenocarcinoma Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/conference-coverage-services